Skip to main content

Cerus Value Stock - Dividend - Research Selection

Cerus

ISIN: US1570851014 , WKN: 905249

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company\'s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Commit To Buy Cerus At $1, Earn 7.6% Annualized Using Options

2023-09-19
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cerus Corporation to Participate in the 2023 Cantor Global Healthcare Conference

2023-09-12
CONCORD, Calif., September 12, 2023--Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, at 10:30 a.m. EST.

Tracking Baker Brothers Portfolio - Q2 2023 Update

2023-08-31
Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. Click here for a detailed analysis.

5 Stocks Wall Street and ARK’s Cathie Wood Love Are Trading Under $10 With Huge Upside Potential

2023-08-26
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cathie Wood’s ARK Funds Are Loading Up on These 5 Red-Hot Stocks Trading Under $10

2023-08-12
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cerus: Profitability Needs To Come Faster As Cash Is Running Out

2023-08-11
Cerus Corporation is struggling to achieve profitability and is running out of cash, likely leading to share dilution. Read more here.

Bluejay, Adamis top healthcare gainers; Aravive, Vicarious among losers

2023-08-03
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cerus Corporation (CERS) Q2 2023 Earnings Call Transcript

2023-08-02
Cerus Corporation (NASDAQ:NASDAQ:CERS) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ETCompany ParticipantsJessica Hanover - Vice President-Corporate AffairsObi Greenman -...

Cerus (CERS) Reports Q2 Loss, Lags Revenue Estimates

2023-08-02
Cerus (CERS) delivered earnings and revenue surprises of -40% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Cerus Corporation Announces Second Quarter 2023 Financial Results

2023-08-02
CONCORD, Calif., August 02, 2023--Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2023.